AbbVie Inc. (NYSE:ABBV) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other analysts have also weighed in on ABBV. Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 target price on shares of AbbVie in a research note on Thursday. Vetr upgraded AbbVie from a “hold” rating to a “buy” rating and set a $76.28 target price on the stock in a research note on Wednesday, July 26th. Cowen and Company set a $70.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Sunday, July 30th. Credit Suisse Group reiterated a “neutral” rating and issued a $74.00 target price (up previously from $65.00) on shares of AbbVie in a research note on Thursday, July 20th. Finally, Leerink Swann set a $71.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Thursday, April 20th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie currently has a consensus rating of “Buy” and an average price target of $75.35.

Shares of AbbVie (ABBV) remained flat at $70.99 on Friday. 4,732,537 shares of the company’s stock were exchanged. The stock has a market capitalization of $112.98 billion, a PE ratio of 13.89 and a beta of 1.50. AbbVie has a 52 week low of $55.06 and a 52 week high of $75.04. The company’s 50 day moving average price is $72.07 and its 200 day moving average price is $66.31.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a return on equity of 154.76% and a net margin of 24.77%. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same quarter last year, the firm posted $1.26 earnings per share. The business’s revenue was up 7.6% compared to the same quarter last year. Equities research analysts predict that AbbVie will post $5.52 EPS for the current fiscal year.

WARNING: “AbbVie Inc. (ABBV) Downgraded by BidaskClub” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/06/abbvie-inc-abbv-downgraded-by-bidaskclub.html.

In related news, EVP Carlos Alban sold 45,800 shares of AbbVie stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $70.00, for a total transaction of $3,206,000.00. Following the completion of the sale, the executive vice president now owns 160,545 shares of the company’s stock, valued at $11,238,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard A. Gonzalez sold 65,861 shares of AbbVie stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total value of $4,676,131.00. Following the sale, the chief executive officer now directly owns 342,353 shares of the company’s stock, valued at approximately $24,307,063. The disclosure for this sale can be found here. In the last three months, insiders sold 406,895 shares of company stock valued at $28,140,423. Corporate insiders own 0.23% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in AbbVie during the fourth quarter worth approximately $823,984,000. State Street Corp increased its stake in AbbVie by 2.4% in the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after buying an additional 1,696,042 shares during the period. Comerica Bank increased its stake in AbbVie by 81.7% in the second quarter. Comerica Bank now owns 1,849,149 shares of the company’s stock worth $136,671,000 after buying an additional 831,625 shares during the period. Wedge Capital Management L L P NC purchased a new stake in AbbVie during the first quarter worth approximately $46,744,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in AbbVie during the fourth quarter worth approximately $41,452,000. 68.00% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.